Phase 3Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME-4)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide vs. Placebo in Participants With Overweight or Obesity and Type 2 Diabetes
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 600 planned
- Conditions
- Obesity or Overweight; Type 2 Diabetes
- Interventions
- Petrelintide; Placebo
- Ages
- adults, older adults
- Registry
- NCT07843485, CTIS2026-526189-25-00
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Primary outcomes
- Percentage Change in Body Weight from Baseline
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered